Identifying risk factors for rubella susceptibility in a population at risk in the United States

American Journal of Public Health

Volumn 93, Issue 2, 2003, Pages 289-291

  Danovaro Holliday, M Carolina ^a   Gordon, Ely R ^b   Woernle, Charles ^e   Higginbotham, Gary H ^e   Judy, Randa H ^e   Icenogle, Joseph P ^c   Reef, Susan E ^a,d  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b Brundidge Medical   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; FEMALE; GENDER; HIGH RISK POPULATION; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MEXICO; MIGRANT WORKER; RUBELLA; SEROLOGY; UNITED STATES; VACCINATION;

EID: 0037308453     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.93.2.289     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1998;47(RR-8):1-57.
2. Centers for Disease Control and Prevention. Measles, rubella, and congenital rubella syndrome-United States and Mexico, 1997-1999. MMWR Morb Mortal Wkly Rep. 2000;49(46):1048-1050, 1059.
3. Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis. 2000;31:85-95.
4. Centers for Disease Control and Prevention. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR Morb Mortal Wkly Rep. 2001;50(RR-12):1-23.
5. Danovaro-Holliday MC, Zimmerman L, Reef SE. Observations from the CDC: preventing congenital rubella syndrome (CRS) through vaccination of susceptible women of childbearing age. J Womens Health Gender-Based Med. 2001;10:617-619.
6. World Health Organization. Preventing congenital rubella syndrome. Weekly Epidemiol Rec. 2000;75:290-296.
7. Rangel MC, Sales RM, Valeriano EN. Rubella outbreaks among Hispanics in North Carolina: lessons learned from a field investigation. Ethn Dis. 1999;9:230-236.
8. Centers for Disease Control and Prevention. Rubella among Hispanic adults-Kansas, 1998, and Nebraska, 1999. MMWR Morb Mortal Wkly Rep. 1999;48(RR-8):1-15.
9. Danovaro-Holliday MC, LeBaron CW, Allensworth C, et al. A large rubella outbreak with spread from the workplace to the community. JAMA. 2000;284:2733-2739.
10. Centers for Disease Control and Prevention. Public health dispatch: varicella outbreaks among Mexican adults-Alabama, 2000. MMWR Morb Mortal Wkly Rep. 2000;49(32):735-736.
11. Helfand RF, Keyserling HL, Williams I, et al. Comparative detection of measles and rubella IgM and IgG derived from filter paper blood and serum samples. J Med Virol. 2001;65:751-757.
12. Gutierrez-Trujillo G, Muñoz O, Tapia-Conyer R, et al. Seroepidemiologia de la rubeóla en mujeres Mexicanas: encuesta nacional probabilística [The seroepidemiology of rubella in Mexican women: a national probability survey]. Salud Publica Mex. 1990;32:623-631.
13. Dykewicz CA, Kruszon-Moran D, McQuillan G, Williams WW, Hadler S. Rubella immunity in U.S. adolescents and young adults, 1988-1994. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 28-October 1, 1997; Toronto, Ontario, Canada. Abstract H-147.
14. Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J. 1996;15:687-692.
15. LeBaron CW, Forghani B, Reef SE, et al. Immunogenicity and adverse events of a 2nd dose of rubella vaccine. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 28-October 1, 1997; Toronto, Ontario, Canada. Abstract H-148.
16. Orenstein WA, Herrmann KL, Holmgreen P, et al. Prevalence of rubella antibodies in Massachusetts schoolchildren. Am J Epidemiol. 1986;124:290-298.
17. Matter L, Kogelschatz K, Germann D. Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis. 1997;175:749-755.
18. Skendzel LP. Rubella immunity: defining the level of protective antibody. Am J Clin Pathol. 1996;106:170-174.
19. Serdula MK, Halstead SB, Wiebenga NH, Herrmann KL. Serological response to rubella revaccination. JAMA. 1984;251:1974-1977.
20. Robinson RG, Dudenhoeffer FE, Holroyd HJ, Baker LR, Bernstein DI, Cherry JD. Rubella immunity in older children, teenagers, and young adults: a comparison of immunity in those previously immunized with those ummmunized. J Pediatr. 1982;101:188-191.